Publikationen, an denen er mitarbeitet Jordi Bruix Tudó (19)

2024

  1. Evidence and choice: The BCLC vision for tailoring clinical decision-making

    Journal of Hepatology

2023

  1. Nivolumab Plus Cabozantinib with or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results from Cohort 6 of the CheckMate 040 Trial

    Journal of Clinical Oncology

2022

  1. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update

    Journal of Hepatology, Vol. 76, Núm. 3, pp. 681-693

  2. Reply to: “An EASL position paper for systemic treatment of hepatocellular carcinoma: Go forward courageously”

    Journal of Hepatology

  3. What to do about hepatocellular carcinoma: Recommendations for health authorities from the International Liver Cancer Association

    JHEP Reports, Vol. 4, Núm. 12

2021

  1. Assessing the impact of COVID-19 on liver cancer management (CERO-19)

    JHEP Reports, Vol. 3, Núm. 3

  2. Corrigendum to “Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules” [J Hepatol (2019) 874–884] (Journal of Hepatology (2019) 70(5) (874–884), (S0168827819300157), (10.1016/j.jhep.2019.01.005))

    Journal of Hepatology

  3. Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH

    Medicina Clinica, Vol. 156, Núm. 9, pp. 463.e1-463.e30

  4. Radiological response to nivolumab in patients with hepatocellular carcinoma: A multicenter analysis of real-life practice

    European Journal of Radiology, Vol. 135

  5. Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study

    Journal of Clinical Oncology, Vol. 39, Núm. 27, pp. 2991-3001

  6. Systemic treatment of hepatocellular carcinoma: An EASL position paper

    Journal of Hepatology, Vol. 75, Núm. 4, pp. 960-974

2020

  1. International and multicenter real-world study of sorafenib-treated patients with hepatocellular carcinoma under dialysis

    Liver International, Vol. 40, Núm. 6, pp. 1467-1476

2019

  1. Identification of coding and long noncoding RNAs differentially expressed in tumors and preferentially expressed in healthy tissues

    Cancer Research, Vol. 79, Núm. 20, pp. 5167-5180

  2. Medical treatment for cholangiocarcinoma

    Liver International, Vol. 39, Núm. S1, pp. 123-142

2017

  1. Assessment of treatment efficacy in hepatocellular carcinoma: Response rate, delay in progression or none of them

    Journal of Hepatology

2016

  1. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy

    Journal of Hepatology, Vol. 65, Núm. 4, pp. 719-726

2014

  1. "very early" intrahepatic cholangiocarcinoma in cirrhotic patients: Should liver transplantation be reconsidered in these patients?

    American Journal of Transplantation, Vol. 14, Núm. 3, pp. 660-667

  2. Intrahepatic cholangiocarcinoma or mixed hepatocellular-cholangiocarcinoma in patients undergoing liver transplantation: A spanish matched cohort multicenter study

    Annals of Surgery, Vol. 259, Núm. 5, pp. 944-952

2009

  1. Diagnóstico y tratamiento del carcinoma hepatocelular

    Medicina Clinica, Vol. 132, Núm. 7, pp. 272-287